PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Purushotham & Akther Kotha MD, Inc., La Mesa, California, United States

Valerius Medical Group & Research Center of Greater Long Beach, Inc., Los Alamitos, California, United States

Swati Shah MD Rheumatology, LLC, Jacksonville, Florida, United States

CTR Oakwater, Orlando, Florida, United States

Parris and Associates Rheumatology, Lawrenceville, Georgia, United States

Accurate Clinical Research, Inc., Lake Charles, Louisiana, United States

Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States

Joint and Muscle Research Institute, Charlotte, North Carolina, United States

West Tennessee Research Institute, Jackson, Tennessee, United States

Novel Research LLC, Bellaire, Texas, United States

Liberty Research Center, Dallas, Texas, United States

Integrative Rheumatology of South Texas, Harlingen, Texas, United States

Northwest Houston Arthritis Center, Houston, Texas, United States

Texas Rheumatology Research Institute, LLC, Plano, Texas, United States

Nephrology Leaders and Associates, PLLC, Van Vleck, Texas, United States